Tetratherix™

ASX Release

ASX:TTX

FY26 Results Presentation

20th August 2026

Tetratherix Limited (ASX:TTX) (**Tetratherix**) is pleased to announce its FY26 financial results presentation.

A copy of the CEO letter contained in the Annual Report lodged with ASX on 20 August 2026 is also available on Medium.

< ENDS >

Medium

InvestorHub

The Tetratherix InvestorHub platform provides existing and prospective shareholders with real-time access to ASX announcements, reports and presentations. You can visit the Tetratherix Investor Hub at:

InvestorHub

Authorised for release by the CEO.

For further information contact:

Jacob Pfeffer
General Counsel | Chief of Staff | Company Secretary
+61 425 194 200
jacob.pfeffer@tetratherix.com

Tetratherix™

Tetratherix
FY26 Results Briefing

IMPORTANT INFORMATION & DISCLAIMER

USE OF THIS DOCUMENT
You must read the following notices before reading or making any use of this document or any information contained in this document. By continuing to read, use or otherwise act on this document, you agree to be bound by the following terms and conditions, including any modifications to them, and make or give the acknowledgements, representations or warranties (as applicable). This presentation is provided for information purposes only. The information in this presentation is in a summary form, does not purport to be complete and is not intended to be relied upon as advice to investors or other persons. The information contained in this presentation was prepared by Tetratherix Limited ACN 607 771 077 (Tetratherix) as of its date, and remains subject to change without notice. This presentation has been provided to you solely for the purpose of giving you background information about Tetratherix.

DISTRIBUTION OUTSIDE AUSTRALIA
The distribution of this presentation to persons or in jurisdictions outside Australia may be restricted by law and any person into whose possession this document comes should seek advice on and observe those restrictions. Any failure to comply with such restrictions may violate applicable securities law.

FORWARD-LOOKING STATEMENTS
This presentation may include forward looking statements. Such statements can generally be identified by the use of words such as 'may', 'will', 'expect', 'intend', 'plan', 'estimate', 'anticipate', 'believe', 'continue', 'objectives', 'outlook', 'guidance', 'forecast' and similar expressions. Indications of plans, strategies, management objectives, revenue and financial performance are also forward-looking statements. Such statements are not guarantees of future performance, and involve known and unknown risks, uncertainties, significant items of subjective judgement, assumptions (including in relation to future events that may or may not eventuate), contingencies and other factors, many of which are outside the control of Tetratherix. No independent third party has reviewed the reasonableness of any such statements or assumptions. No representation is made or will be made that any forward-looking statements will be achieved or will prove to be correct. Actual results, performance, operations or achievements may vary materially from any forward-looking statements. Circumstances may change and the contents of this presentation may become outdated as a result. Readers are cautioned not to place undue reliance on forward looking statements. Except as required by law, Tetratherix assumes no obligation to release updates or revisions to forward looking statements to reflect any changes. You should form your own views as to these matters and any assumptions on which such statements are based and not place reliance on such statements. No representation or warranty, expressed or implied, is made as to the accuracy, reliability, adequacy or completeness of the information contained in this presentation. To the maximum extent permitted by law, Tetratherix excludes and disclaims all liability, including (without limitation) any liability for fraud or negligence, for any expenses, losses, damages or costs incurred either as a result of the information in this presentation being inaccurate or incomplete in any way for any reason, or otherwise arising in connection with this presentation.

PAST PERFORMANCE AND RISKS
Past performance information given in this presentation is given for illustrative purposes only and should not be relied upon as (and is not) an indication of future performance. An investment in Tetratherix is subject to known and unknown risks, some of which are beyond the control of Tetratherix, including factors and risks specific to the industry in which it operates as well as general economic conditions, prevailing exchange rates and interest rates and conditions in the financial markets. Tetratherix does not guarantee any particular rate of return on its performance nor does it guarantee any particular tax treatment. Prospective investors should make their own enquiries and investigations regarding all information in this presentation, including the assumptions, uncertainties and contingencies which may affect future operations and the impact that different future outcomes may have on Tetratherix.

NO OFFER, INVITATION OR ADVICE
This presentation is not, and is not intended to constitute, financial advice, or an offer or an invitation, solicitation or recommendation to acquire or sell Tetratherix shares or any other financial products in any jurisdiction and is not a prospectus, product disclosure statement, disclosure document or other offering document under Australian law or any other law. This presentation does not form the basis of any contract or commitment to sell or apply for securities in Tetratherix or any of its subsidiaries. It is for information purposes only. Tetratherix does not warrant or represent that the information in this presentation is free from errors, omissions or misrepresentations or is suitable for your intended use. The information contained in this presentation has been prepared without taking account of any person's investment objectives, financial situation or particular needs and nothing contained in this presentation constitutes investment, legal, tax or other advice. The information provided in this presentation may not be suitable for your specific needs and should not be relied upon by you in substitution of you obtaining independent advice. Subject to any terms implied by law and which cannot be excluded, Tetratherix accepts no responsibility for any loss, damage, cost or expense (whether direct, or indirect, consequential, exceptional or special damages including but not limited to loss of revenue, profits, time, goodwill, data, anticipated savings, opportunity, business reputation, future reputation, production or profit, any delay costs, economic loss or damage) incurred by you as a result of any error, omission or misrepresentation in this presentation.

UNAUDITED INFORMATION
All forward-looking figures and proforma statements in this presentation are unaudited. Certain figures may be subject to rounding differences. All market share information in this presentation is based on management estimates having regard to internally available information unless otherwise stated.

PRESENTATION OF INFORMATION
All currency amounts in this presentation are in Australian dollars unless otherwise stated.

Tetratherix™

Who is Tetratherix?

We are an Australian biomedical technology company, founded in 2015 as an advanced manufacturing and intellectual property–generating entity in the biomaterial and regenerative medicine space. At our core, we have our flagship Tetramatrix™ platform technology.

We commercialise multiple products derived from our Tetramatrix™ platform technology through a flywheel model in which our established foundational intellectual property, safety, efficacy, and streamlined manufacturing processes facilitate the rapid and efficient development of products in different fields of medicine.

We have been building this company and its platform technology for 15 years, having started the journey as a PhD thesis at the University of Sydney. The founders and inventors of the technology continue to control and drive the company towards its mission.

The Tetratherix Mission

Our goal is to derive products from our platform technology to expand healthcare access by treating more patients outside traditional hospital and surgical settings, fostering greater health equity worldwide and improving clinical outcomes.

We use the modularity of the Tetramatrix™ platform to partner with key market leaders to develop new technologies and together maximise impact.

We will treat 10 million patients by 2035 by using our platform technology.

TTX Timeline – 15 Years in the Making



The TTX Decade Development Arc

Fifteen years of deliberate work sit behind the milestone stack. Every step was sequenced so it would build on the one before, carrying us steadily from early science towards commercial scale. The structure moves us into commercialisation and the generational patient impact we set out to create.

TTX by the numbers

Active Product Programs



15
Years of deep R&D on the cusp of changing lives around the world

6
Products being developed from a single technology in the first generation

3X
Enhanced productivity With flywheel in motion from experience and AI/ digitalisation

03
New chemistries with 95% similarities from our single Tetramatrix Platform technology

Global R&D Infrastructure

10
Years being ISO:13485 Certified



Digital
Internal Machine Learning Tool*

42
Granted Patents

2044
Patent Expiry Timeframe

*: Embedded internal digital tool to enable effective discovery of new and ongoing opportunities

The Tetramatrix™ Platform Technology

Tetratherix™

The Evolving Dynamics of Global Healthcare Demand Innovative & Cost-Effective Biomaterials

01. Rising Patient Expectations

Patients are increasingly expecting higher quality of care with a particular focus on reducing recovery times and the lower risk of complications – which is also a driver of increasing healthcare costs for patients and payers globally.

02. Need for Cost-Effective and Decentralised Care

Increasing global healthcare spending and demand for healthcare services are necessitating investment in cost-effective tools and treatments, including those that can be delivered outside a traditional hospital setting, to minimise burden on the healthcare system.

03. Easier Healthcare Delivered Wherever Care Happens

Consumers are taking a bigger role in healthcare choices, they are demanding safer, easier options they can use at home or assisted in outpatient settings focused on predictable performance that improves access and outcomes.



Tetramatrix™ Platform Technology

Our Tetramatrix platform is best positioned to address the clinical demands that are central to the evolution

01

Universal Minimally invasive delivery

Water-based solution that can be injected or sprayed into the body without causing disruption to the surrounding host tissue.

02

Seamlessly integrates into existing workflow

Engineered for predictable point-of-care handling without bespoke infrastructure, with controlled transition at physiological temperature for repeatable, measurable and clinically practical performance.

03

Biostealth: Engineered to be ignored

With seamless biocompatibility, Tetramatrix™ works with the body then disappears with no fuss, no noise and nothing left behind.

04

Manufactured at low cost and scaled

Built with manufacturability, robust quality systems and scalability in mind, Tetramatrix™ supports clear pathways from development through to validation and ultimately real-world clinical deployment.

Tetramatrix™



Tetramatrix™ Platform Technology

Tetramatrix™ is a synthetic material supplied in a ready-to-use syringe format that fits within the existing clinical workflow rather than changing it. It is manufactured locally, at scale and at low cost.

01 Intelligent

The material is an injectable fluid to avoid causing damage to the body during its application. Upon injection, triggered by physiological temperature, a 3D matrix is formed that physically integrates and adheres to the target tissue.

02 Modular

A biomaterial platform built with unique polymer programming akin to 'medical Lego®' to form implantable products to solve a wide range of clinical problems.

03 Biomimetic

The matrix has similar water content and mechanical properties to natural tissue, and therefore is impervious to the body, bridging healthy and injured tissues, helping heal injuries or physically manipulating the body during surgical interventions.

Tetramatrix™



Tetramatrix™ Clinical Franchises built on a single platform

The Tetramatrix™ platform is applied across four distinct clinical use cases we call franchises. In practice, we do what a material can usefully do inside the body: we help repair both soft and hard tissue, we deliver therapeutics, and we create and hold surgical space. Our products are developed to go deeper within each application rather than broader across many, so that every derivative is refined for the clinical problem it solves.

A. Same Technology

B. Multiple Opportunities

1 Bone Regeneration

Bone Regeneration products on the Tetramatrix™ platform are flowable bone extenders for dental and orthopaedic defects where placement and retention matter. They set into a tissue-conductive matrix that host cells grow through, integrating biologically.



2 Tissue Healing

Tissue Healing products on the Tetramatrix™ platform integrate physically and biologically with soft tissue anywhere in the body, forming a synthetic, inert bridge channelling new tissue in. Clinically explored for incisional scar prevention, with potential in spine, cartilage and tendon.

3 Tissue Spacing

Tissue Spacing products on the Tetramatrix™ platform create and maintain surgical space, injected simply and visible under multiple conditions. Their stability, resorption and modularity span needs from radiation therapy to cataract microsurgery.



4 Precision Medicine

STEPP, our first Precision Medicine product, is a sprayable Tetramatrix™ system for intranasal delivery — clinically reproducible, minimally invasive, easy to use. It protects the compound, forms an adhesive nasal cushion and speeds bloodstream uptake.

Tetramatrix™ Product Portfolio Generation 1

Our Generation 1 products are the first commercial derivatives of the Tetramatrix™ platform, each engineered from the same core chemistry for a specific clinical need. They span all four franchises: Tegenix and TegenEOS for bone regeneration, Tutelix and Optimatrix for tissue spacing, TetraDerm for tissue healing, and STEPP for precision medicine. Together they show how a single platform technology can be programmed into distinct, purpose-built products across a broad range of surgical and therapeutic settings.



Bone Regeneration	Tissue Spacing	Tissue Healing	Precision Medicine
Tegenix	Tutelix	TetraDerm	STEPP
TegenEOS	Optimatrix		

FY26 Results & Highlights

Tetratherix™

FY26 Financial Highlights

A capital light model with compounding revenue

This business was built lean from the outset, not reshaped into it during FY26. We don't carry the cost of owning commercialisation, regulatory filings or market access in every territory; our partners do, and they're better resourced to do it than we ever would be. What we hold onto is the part of the value chain that scales without adding cost: a single Tetramatrix™ chemistry, licensed and supplied into every derivative product the platform can support. That's why our licence and supply revenue runs at a gross margin most product companies can't match, and why it gets more profitable as it grows rather than just bigger — each new partner adds revenue on essentially the same fixed cost base, without a new commercial team or regulatory function built to support them.

This unique and attractive model is enabled by:

- A platform technology that allows parallel developments
- Advanced manufacturing with economies of scale
- Partnerships with leading players who are motivated to sell over a long time
- A patient & deliberate strategy





FY26 Financial Highlights

Cashflow: $15.6m (before costs) from May 2026 placement plus $4.2m Superpower Licence Revenue has funded incremental growth over and above the IPO strategic plan

1 $20.5 million (87%) of cash inflows are incremental to the Prospectus assumptions and will be used to expedite manufacturing expansion and investment in digital and customer success



✳ Incremental inflow to prospectus

2 R&D investment $5.1 million, 31% of total cash outflows driven by Bone Regeneration progress towards FDA 510(k) clearance and the Precision Medicine addition to the portfolio in FY26

FY26 Operational Highlights

01

58% Growth in Patient Impact

Patient impact is how we measure our success. Tetramatrix™ platform technology has now been used across multiple clinical trials with over 75 patients included. This number will significantly grow upon market clearance in 2026.

02

First Revenues of $4.2m*

Reaching the commercial inflection point. Tetratherix is now officially a revenue generating business, having successfully transitioned from an R&D house to a commercial entity.

03

Completed First FDA Submission

Significant regulatory milestone met. 2026 saw TTX complete its first full FDA dossiers including performance and safety testing for our dental and orthopaedic bone regeneration products for initial market launch in the US.

04

Production Readiness Underway

Federal Government support for Australian Export. With the support of a $3.3m IGP grant, we have now begun the build of our bespoke advanced manufacturing facility to increase our capabilities by 10x in Sydney, Australia with completion estimated to be in late 2026.

05

Precision Medicine Launch

Changing the way drugs are delivered on the back of 5+ years of mRNA delivery research. Tetratherix has now launched its drug delivery franchise, targeting the exciting intersection of consumer preventative medicine and metabolic health.

06

Paving the Path with our Pipeline

Growing patient impact, anchored by science. Working closely with our development partners, TTX has progressed the clinical safety & efficacy testing for its pipeline products in scar prevention, urological spacing and cataract surgeries.

*The $4.2 million licence revenue is being recognised on a straight-line basis over the 12-month period from April 2026. Of this, $0.9 million has been recognised in the FY26 P&L, with the remaining $3.3 million to be recognised in FY27.

FY26 Operational Highlights

01

58% Growth in Patient Impact

Patient impact is how we measure our success. The Tetramatrix™ platform has now been used across multiple clinical trials, with more than 75 patients treated to date, and that number is set to grow considerably once we reach market clearance in 2026.

Across the year the TetraDerm clinical trial advanced into cohorts 2 and 3, with major wounds now being treated and with strong indications of performance in reducing scar formation. The Tutelix pilot trial was completed with 15 patients treated, recording no adverse events to date, outstanding clinical usability outcome and space generating capability. Human Research Ethics Committee approval was granted for the Tutelix pivotal trial towards the product clearance with the FDA.

A. Tutelix First In Human Success

The first in human (FIH) clinical trial for Tutelix product was initiated and all planned 15 patients completed their treatment with no product related adverse event. The product administration was successfully completed for all patients across two sites in Australia. The visibility of the product once injected provided a safe and easy to use product for the clinicians while the mechanical performance of the forming hydrogel and its "lift" strength formed an homogeneous space anatomically between prostate and other tissues.

Tutelix Clinical Performance Confirmed



A. Tutelix First In Human Success

Product displayed an outstanding structural stability at the injection site for 3 months. MRI results displayed "water intake" at this time point which is a prerequisite for over time hydrolysis and resorption of the injected structure. The uniformity of the structure and its stability for at least 3 months can provide solid basis to expand the application of the technology for pelvic cancer.



Tutelix stability results unlock Expansion of the Oncology Spacing opportunity

B. TetraDerm Clinical Trial Progress

TetraDerm Clinical Trial progressed in two sites in Australia. The results from the unblinded cohort 1 showed strong indications of efficacy for the technology to reduce scar formation. No report of inflammation, seroma formation and no report of hypertrophic scarring are all aligned with the expected mode of action for TetraDerm.

70
years of age
Oldest patient treated in the trial with VSS of <1 at all time points

9
cm wound length
Relatively large wounds with no healing issues observed

0
seroma formation
No reports of seroma formation in any of the treated wounds

ZERO
inflammation
No reports of inflammation from 2 weeks onwards in any of the patients

TetraDerm Opportunity Validated

Operation



1 Week



6 Weeks



6 Months



12 Months



Cohort 2 recruitment with 18 patients completed and significant progress has been achieved in cohort 3 that involves up to 1.5 m wounds after breast augmentation, belt lipectomy and other major surgeries.

FY26 Operational Highlights

02

First Revenues of $4.2m*

Reaching the commercial inflection point. Tetratherix is now a revenue-generating business, having made the transition from an R&D house to a commercial entity.

This first revenue is an annual licensing fee that gives a single partner access to our intellectual property, and it establishes a model we can extend as further partners are added across the entire platform. Supply of the Tetramatrix™ platform polymer will build on this base, adding a second stream to our revenue-generating potential.

*The $4.2 million licence revenue is being recognised on a straight-line basis over the 12-month period from April 2026. Of this, $0.9 million has been recognised in the FY26 P&L, with the remaining $3.3 million to be recognised in FY27.

FY26 Operational Highlights

03

Completed First FDA Submissions

A significant regulatory milestone met. In 2026 Tetratherix completed its first full FDA dossiers, covering the performance and safety testing for our dental and orthopaedic bone regeneration products ahead of their initial market launch in the United States.

The submissions were completed on the back of multiple pre-submission meetings with the FDA and draw on 27 internal reports, the full suite of ISO 10993 preclinical safety studies, and two large-animal performance studies. Completing this work sets the regulatory flywheel in motion and makes each future submission easier to prepare. It is a licence to hunt and the beginning of a longer journey.



FDA U.S. FOOD & DRUG ADMINISTRATION

FDA submission Data Read out

As a novel platform material, and to enable effective and efficient motion of our flywheel for our current and future FDA submissions, we went above and beyond to confirm the safety of our polymer platform per ISO10993. An independent review of data with a biological safety scientist and a principal toxicologist in the US concluded that the platform is safe, based on a weight-of-evidence assessment from numerous in vivo studies, and demonstrated no evidence of irritation, sensitisation, systemic toxicity, genotoxicity, pyrogenicity or carcinogenicity from the platform.

Tegenix Excels in FDA Performance Study



FDA submission Data Read out

FDA U.S. FOOD & DRUG ADMINISTRATION

The sites were integrated with the host tissue, and the Tegenix treated sites demonstrated the product's proposition, allowing bone ingrowth within the grafted site, leading to greater bone volume.

Greater Volume of Bone with Tegenix vs predicate



FDA submission Data Read out

FDA U.S. FOOD & DRUG ADMINISTRATION

The results from these clinically relevant models confirmed that Tegenix: (a) acts as an effective carrier for any type of bone grafts (animal or human-derived) to enhance their usability and handling; (b) supports natural healing with no inflammatory/ foreign body reaction to Tegenix; and (c) provides a 3D matrix to hold them in place to enable cellular ingrowth and activation. The impact was more evident where adhesivity of Tegenix matrix plays an important role (for example in upper jaw).



Tegenix Mechanism of Action Confirmed

FDA submission Data Read out

U.S. FOOD & DRUG ADMINISTRATION

TegenEOS allows effective delivery of autografts to the site for effective integration of the newly formed bone with the host environment (turquoise blue area showed the original location of the defect).



TegenEOS Excels in FDA Performance Study

FY26 Operational Highlights

04

Production Readiness Underway

Federal Government support for Australian export. With the backing of a $3.3m Industry Growth Program grant, we have begun building a purpose-designed advanced manufacturing facility in Sydney that will lift our production capability tenfold, with completion expected in late 2026.

The facility adds 3,000 sqm of production space to our campus and positions Tetratherix to be a leader in innovation for Australian advanced manufacturing, exporting globally. Capacity is being brought online in stages to match global demand, and inventory is being built through the process to supply both the Bone Regeneration and Precision Medicine franchises.

FY26 Operational Highlights

05

Precision Medicine Launch

Changing the way drugs are delivered, on the back of more than five years of mRNA delivery research. Tetratherix has launched its Precision Medicine franchise, targeting the intersection of consumer preventative medicine and metabolic health.

The franchise is built on years of complex pharmaceutical R&D and collaboration with big pharma on mRNA delivery. The technology's distinctive feature is the ability to hold active compounds in place for controlled nasal delivery, avoiding injection entirely. Anchored by science, the technology's proposition has been validated by recent peer-reviewed publications covering the nasal delivery of proteins, peptides and insulin.



FY26 Operational Highlights

06

Paving the Path with our Pipeline

Growing patient impact, anchored by science. Working closely with our development partners, Tetratherix advanced the clinical safety and efficacy testing of its pipeline products across scar prevention, urological spacing and cataract surgery.

In addition to our clinical trials for TetraDerm and Tutelix, that both reached significant clinical milestones, we continued the development of our other pipeline products. BioOptix completed its proof-of-concept preclinical studies, demonstrating that the product can maintain surgical space and allow complete cataract surgery with no spike in eye pressure. We published our results in multiple peer-reviewed journal articles on novel utility of our polymer platform for tissue healing and precision medicine.

The Tetramatrix™ platform continues to grow



A histological assessment of a pipeline Tissue Healing application in an animal model from UPenn (USA)

FY26 – A year of relentless execution of the TTX Mission

3
New Critical Partnerships

2
Clinical Trials

$20m
Additional Balance Sheet Strength

2
Bone Regen Products ready for launch

* Incremental to prospectus milestones

Directional Momentum



The Opportunity Ahead

Tetratherix™

Tetramatrix™ Product Portfolio Generation 1

Our Generation 1 products are the first commercial derivatives of the Tetramatrix™ platform, each engineered from the same core chemistry for a specific clinical need. They span all four franchises: Tegenix and TegenEOS for bone regeneration, Tutelix and Optimatrix for tissue spacing, TetraDerm for tissue healing, and STEPP for precision medicine. Together they show how a single platform technology can be programmed into distinct, purpose-built products across a broad range of surgical and therapeutic settings.




Bone Regeneration	Tissue Spacing	Tissue Healing	Precision Medicine
Tegenix	Tutelix	TetraDerm	STEPP
TegenEOS	Optimatrix		

Product Segmentation – Generation 1

Multiple Compounding Opportunities

- First application to market
- Rapid Displacement via venture partnership
- Scaled Disruption with commercial partner

Size of bubble reflects TAM Opportunity

Combined TAM ~$12.5bn



Bone Regeneration

Tetratherix™

Product Segmentation – Generation 1



Bone Regeneration

Tegenix anchors the bone-regeneration franchise. **It's predicted to be the first product through FDA clearance,** entering a bone-graft substitute market worth ~US$0.6B (2025), with Henry Schein already lined up to carry it into first commercial sales.

TegenEOS carries a **materially larger opportunity,** because it's dual-application, not bone-only. The core bone-graft TAM is ~US$0.8B (2025), growing to US$1.8–2.0B by the early 2030s on the back of ~5 million US implant procedures a year — and the same matrix extends into **PRP delivery, an underserved US$1.0–1.7B (2025) market growing 13–15% annually** across orthopaedics, sports medicine, dental and aesthetics, by **solving the retention problem** that limits free-injection PRP today.

TegenEOS is classified as a Disrupt asset, not an incremental one. An injectable, resorbable matrix changes the procedure itself, rather than making an existing delivery method marginally better.

First Product Revenues in FY27

Tissue Spacing

Tetratherix™

Product Segmentation – Generation 1



Tissue Spacing

Tutelix is the clearest Displace case. It enters the established hydrogel-spacer category (SpaceOAR, Barrigel) with a **safer, reversible, differentiated product**, addressing a ~US$1 billion opportunity (~750,000 patients) consistent with ~350,000 annual global prostate radiotherapy procedures plus expansion into other pelvic applications — with a **mid-term time to revenue** given an existing reimbursement and regulatory template to follow.

Optimatrix starts narrow against a **very large population.** Cataract surgery runs at **~28–30 million procedures a year** within a ~US$17 billion ophthalmic drug delivery market, but its initial indication is deliberately early and narrow, and it's classed as Displace, entering an existing category desperate for innovation. The real upside is indication breadth — as the addressable indication widens, both patient impact and TAM grow materially. **The biggest player in the market is already on board with an R&D funding agreement to accelerate our path to meaningful revenue.**

#1 Partnership will drive acceleration to market

Tetratherix™

Product Segmentation – Generation 1



Tissue Healing

TetraDerm is high impact and relatively mid-term to revenue. **Scarring affects almost every surgical patient and there is no strong intraoperative incumbent,** so TetraDerm reads as a category creator (Disrupt).

The overall **scar-treatment market is large** — around US$19 billion in 2025, heading toward roughly US$43 billion by 2035 — and the intraoperative-matrix slice that TetraDerm serves is a fraction of that, giving an addressable opportunity in the order of US$5 billion. Its regulatory and adoption pathways as a surgical adjunct are relatively mid-term.

Global partnership window now open in FY27

Precision Medicine

Tetratherix™

Product Segmentation – Generation 1



Precision Medicine

STEPP is the portfolio's largest opportunity and clearest disruptor. It starts as a needle-free systemic delivery platform but will be expanded to other routes and a wide range of applications.

It addresses a **very large patient population across many drug classes, with high unmet needs.** The horizon one to access the market and generate revenue is relatively soon in the US. This will follow with additional regulatory engagements and partnerships for longer term development activities.

The published intranasal delivery market is roughly US$63–93 billion today; STEPP's long-horizon, platform-level potential is far larger, and is best framed as a vision TAM rather than a served market.

Biggest near term opportunity of the platform

FY27 – The year TTX transitions to commercialisation

Directional Momentum